Immunological follow up of 13 patients with rheumatoid arthritis treated by anti-T CD4+ monoclonal antibodies

Racadot, E; Wijdenes, John; Wendling, Daniel; Girard, Alexandre; Lienard, Agnès; Peters, A

doi:10.1016/0896-8411(92)90087-7

Cited by 5 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although in open studies more or less promising results have been obtained with CD4 mAb treatment of rheumatoid arthritis (RA) (23)(24)(25), systemic lupus erythematosus (26), Crohn's disease (26a), and multiple sclerosis (MS) 1 patients (27)(28)(29), in double-blind, placebo-controlled, phase II trials with RA patients the efficacy appeared to be absent or very low (30,31). Recently, absence of therapeutic effect was also documented in a randomized, doubleblind, placebo-controlled, magnetic resonance imaging (MRI)-monitored phase II trial in which MS patients were treated with the chimeric CD4 mAb cM-T412 (32).…”

Section: Cd4mentioning

confidence: 99%

Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans.

et al. 1997

View full text Add to dashboard Cite

show abstract

Section: Cd4mentioning

confidence: 99%

Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans.

et al. 1997

View full text Add to dashboard Cite

show abstract

“…The patients were treated with different dose schemes : after the poor result of the first patient treated with 10 mg/day, an increase of the dose was required to evaluate clinical effect and biological modifications especially the percentage of opsonised CD4 cells (17).…”

Section: Discussionmentioning

confidence: 99%

“…More on immunological evaluation (cytokines, lymphocyte proliferation) free and bound Mab may be found elsewhere (17).…”

Section: Immunological Follow-upmentioning

confidence: 99%

Treatment of rheumatoid arthritis with anti CD4 monoclonal antibody. Open study of 25 patients with the B-F5 clone

et al. 1992

Self Cite

View full text Add to dashboard Cite

Twenty-five defined severe RA patients (pts) (17 F, 8 M) were treated in an open study with a CD4 murine monoclonal antibody (Mab) (B-F5 clone, IgG1). Mab's daily dose was 10 mg (1 pt), 15 mg (2 pts), 20 mg (17 pts), 30 mg (4 pts) and 50 mg (1 pt) for 10 days. Tolerance was fair. Clinical improvement occurred during treatment period or within the first month in all but 2 patients, irrespective of Mab dosage. Improvement duration was variable (1 to 12 months), half of the patients still show signs of improvement at month 4. Biological parameters (CRP) improved parallel to the clinical. At day 180, 25% of the patients showed a reduction of 50% or more of the initial CRP values. There is no modification of RF titers, renal and hepatic parameters. Sequential evaluation showed a decrease of B, TCD3, CD4, CD8 lymphocytes and monocytes two hours after Mab infusion and return to baseline in 20 hours. Xenogenic immunization occurred in 6 patients without influence upon clinical response. These modifications are moderate and transient and do not account for the more prolonged effect in some cases, nor do they offer any prediction of further clinical response.

show abstract

“…As numerous experimental autoimmune diseases in rodents and primates can be controlled effectively by CD4-MoAb treatment [12. 13], pilot studies were performed with murine CD4 MoAb in patients with RA [14][15][16][17][18][19], Subsequently studies with chimeric and humanized MoAb were performed [20][21][22] in order to reduce immunogenicity and to increase the interaction with human effector mechanisms [23,24]. The treatment was well tolerated and appeared to have a beneficial effect on arthritis activity.…”

Section: Introductionmentioning

confidence: 99%

Treatment of Rheumatoid Arthritis with a Chimeric CD4 Monoclonal Antibody (cM‐T412): Immunopharmacological Aspects and Mechanisms of Action

et al. 1994

View full text Add to dashboard Cite

To investigate the mechanisms of action underlying the therapeutic effect of CD4 monoclonal antibody therapy in rheumatoid arthritis (RA), clinical responses were compared with several laboratory parameters. Twenty-nine RA patients received either 10 mg, 50 mg or 100 mg of cM-T412, a chimeric CD4 MoAb, for 7 days. The CD4 binding sites on circulating lymphocytes were saturated directly with cM-T412 and serum levels of unbound cM-T412 accumulated towards day 7 of treatment only in the patients treated with 50 and 100 mg. The treatment induced an instant and prolonged depression of the number of circulating CD4+ cells, similar for all dosages. Clinical improvement was observed predominantly in the patients treated with 50 or 100 mg cM-T412 daily and did not correlate with changes in counts of circulating leucocyte subsets nor with changes in serum cytokine levels. An antiglobulin response against cM-T412 developed in a majority of the patients. Side effects on the first day of treatment were correlated with an increase of serum IL-6 levels. This study indicates that a favourable clinical effect of cM-T412 administration was associated with the presence of unbound cM-T412 in the circulation of RA patients. Therefore penetration of unbound cM-T412 into the site of inflammation might determine the therapeutic effect in RA.

show abstract

Immunological follow up of 13 patients with rheumatoid arthritis treated by anti-T CD4+ monoclonal antibodies

Cited by 5 publications

References 0 publications

Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans.

Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans.

Treatment of rheumatoid arthritis with anti CD4 monoclonal antibody. Open study of 25 patients with the B-F5 clone

Treatment of Rheumatoid Arthritis with a Chimeric CD4 Monoclonal Antibody (cM‐T412): Immunopharmacological Aspects and Mechanisms of Action

Contact Info

Product

Resources

About